Ultan McDermott

60.4k total citations · 6 hit papers
94 papers, 13.0k citations indexed

About

Ultan McDermott is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Ultan McDermott has authored 94 papers receiving a total of 13.0k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Molecular Biology, 33 papers in Oncology and 27 papers in Cancer Research. Recurrent topics in Ultan McDermott's work include Cancer Genomics and Diagnostics (25 papers), Lung Cancer Treatments and Mutations (17 papers) and Computational Drug Discovery Methods (11 papers). Ultan McDermott is often cited by papers focused on Cancer Genomics and Diagnostics (25 papers), Lung Cancer Treatments and Mutations (17 papers) and Computational Drug Discovery Methods (11 papers). Ultan McDermott collaborates with scholars based in United Kingdom, United States and Netherlands. Ultan McDermott's co-authors include Michael R. Stratton, Mathew J. Garnett, Sridhar Ramaswamy, Cyril H. Benes, Simon Forbes, Nidhi Bindal, Daniel A. Haber, Patricia Greninger, Jeffrey Settleman and Jeff Settleman and has published in prestigious journals such as New England Journal of Medicine, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Ultan McDermott

93 papers receiving 12.8k citations

Hit Papers

Genomics of Drug Sensitivity in Cancer (GDSC): a resource... 2009 2026 2014 2020 2012 2010 2014 2009 2013 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells
    2012 2.6k citations Wanjuan Yang, Jorge Soares et al. Nucleic Acids Research profile →
  2. A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
    2010 1.8k citations Sreenath V. Sharma, Diana Lee et al. Cell profile →
  3. COSMIC: exploring the world's knowledge of somatic mutations in human cancer
    2014 1.7k citations Simon Forbes, Nidhi Bindal et al. Nucleic Acids Research profile →
  4. Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
    2009 1.5k citations Alice T. Shaw, Beow Y. Yeap et al. Journal of Clinical Oncology profile →
  5. Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition
    2013 457 citations Alexandre Puissant, Stacey M. Frumm et al. Cancer Discovery profile →
  6. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
    2014 427 citations Ultan McDermott et al. Nature Communications profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ultan McDermott United Kingdom 39 8.2k 4.8k 3.9k 3.6k 1.1k 94 13.0k
Cyril H. Benes United States 49 7.4k 0.9× 4.0k 0.8× 2.9k 0.8× 2.5k 0.7× 906 0.8× 123 10.9k
Simon Forbes United Kingdom 21 7.6k 0.9× 2.8k 0.6× 2.2k 0.6× 4.0k 1.1× 798 0.7× 46 11.2k
Sarat Chandarlapaty United States 51 6.3k 0.8× 6.0k 1.2× 4.1k 1.1× 2.9k 0.8× 454 0.4× 205 12.6k
Aik Choon Tan United States 56 6.8k 0.8× 4.5k 0.9× 2.0k 0.5× 2.8k 0.8× 430 0.4× 262 12.1k
Mathew J. Garnett United Kingdom 38 7.1k 0.9× 3.1k 0.6× 1.7k 0.5× 1.9k 0.5× 1.5k 1.3× 85 9.8k
Michael A. Davies United States 57 7.4k 0.9× 6.9k 1.4× 2.6k 0.7× 1.9k 0.5× 661 0.6× 325 12.3k
Barry S. Taylor United States 46 5.5k 0.7× 3.3k 0.7× 2.7k 0.7× 3.0k 0.8× 370 0.3× 118 9.9k
Jeffrey R. Infante United States 63 6.9k 0.8× 9.0k 1.8× 3.5k 0.9× 2.5k 0.7× 491 0.4× 343 14.8k
Jeff Settleman United States 38 10.6k 1.3× 10.8k 2.2× 8.5k 2.2× 5.1k 1.4× 507 0.5× 66 20.5k
Brian Schwartz United States 47 7.7k 0.9× 5.2k 1.1× 5.8k 1.5× 3.3k 0.9× 307 0.3× 143 14.4k

Countries citing papers authored by Ultan McDermott

Since Specialization
Citations

This map shows the geographic impact of Ultan McDermott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ultan McDermott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ultan McDermott more than expected).

Fields of papers citing papers by Ultan McDermott

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ultan McDermott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ultan McDermott. The network helps show where Ultan McDermott may publish in the future.

Co-authorship network of co-authors of Ultan McDermott

This figure shows the co-authorship network connecting the top 25 collaborators of Ultan McDermott. A scholar is included among the top collaborators of Ultan McDermott based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ultan McDermott. Ultan McDermott is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Łukasiak, Sebastian, Alex T. Kalinka, Nikhil Gupta, et al.. (2025). A benchmark comparison of CRISPRn guide-RNA design algorithms and generation of small single and dual-targeting libraries to boost screening efficiency. BMC Genomics. 26(1). 198–198. 3 indexed citations
2.
Grassi, Elena, Aikaterini Chatzipli, Emre Karakoç, et al.. (2024). Integrative ensemble modelling of cetuximab sensitivity in colorectal cancer patient-derived xenografts. Nature Communications. 15(1). 9139–9139. 5 indexed citations
3.
Martin, Matthew J., Nicolas Floc’h, Matthias Pfeifer, et al.. (2022). Pharmaceutical Reactivation of Attenuated Apoptotic Pathways Leads to Elimination of Osimertinib Drug-Tolerant Cells. Cancer Research Communications. 2(10). 1312–1325. 6 indexed citations
4.
McDermott, Ultan. (2019). Large-scale compound screens and pharmacogenomic interactions in cancer. Current Opinion in Genetics & Development. 54. 12–16. 4 indexed citations
5.
Dastur, Anahita, Carlotta Costa, August Williams, et al.. (2018). NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263. Clinical Cancer Research. 25(1). 312–324. 16 indexed citations
6.
Verma, Ajay, Daniel Fernández-García, Panchali Sarmah, et al.. (2018). Circulating tumor DNA in patients with colorectal adenomas: assessment of detectability and genetic heterogeneity. Cell Death and Disease. 9(9). 894–894. 38 indexed citations
7.
Quispel-Janssen, Josine M.M.F., Jitendra Badhai, Stacey Price, et al.. (2017). Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition. Clinical Cancer Research. 24(1). 84–94. 32 indexed citations
8.
Ball, Richard Y., Gunes Gundem, Krishna Sethia, et al.. (2015). Mutation detection in formalin-fixed prostate cancer biopsies taken at the time of diagnosis using next-generation DNA sequencing. Journal of Clinical Pathology. 68(3). 212–217. 18 indexed citations
9.
Puissant, Alexandre, Stacey M. Frumm, Gabriela Alexe, et al.. (2013). Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition. Cancer Discovery. 3(3). 308–323. 457 indexed citations breakdown →
10.
He, Lei, Kristine Torres‐Lockhart, Nicole Forster, et al.. (2012). Mcl-1 and FBW7 Control a Dominant Survival Pathway Underlying HDAC and Bcl-2 Inhibitor Synergy in Squamous Cell Carcinoma. Cancer Discovery. 3(3). 324–337. 54 indexed citations
11.
Yang, Wanjuan, Jorge Soares, Patricia Greninger, et al.. (2012). Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Research. 41(D1). D955–D961. 2597 indexed citations breakdown →
12.
Lee, J., Ben S. Wittner, Morgan L. Maeder, et al.. (2011). Induction of Stable Drug Resistance in Human Breast Cancer Cells Using a Combinatorial Zinc Finger Transcription Factor Library. PLoS ONE. 6(7). e21112–e21112. 11 indexed citations
13.
Sharma, Sreenath V., Diana Lee, Bihua Li, et al.. (2010). A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations. Cell. 141(1). 69–80. 1828 indexed citations breakdown →
14.
McDermott, Ultan, Raju V. Pusapati, James G. Christensen, Nathanael S. Gray, & Jeff Settleman. (2010). Acquired Resistance of Non–Small Cell Lung Cancer Cells to MET Kinase Inhibition Is Mediated by a Switch to Epidermal Growth Factor Receptor Dependency. Cancer Research. 70(4). 1625–1634. 129 indexed citations
15.
McLornan, Donal P., Helen L. Barrett, Robert Cummins, et al.. (2010). Prognostic Significance of TRAIL Signaling Molecules in Stage II and III Colorectal Cancer. Clinical Cancer Research. 16(13). 3442–3451. 64 indexed citations
16.
Gandhi, Leena, Kate L. McNamara, Danan Li, et al.. (2009). Sunitinib Prolongs Survival in Genetically Engineered Mouse Models of Multistep Lung Carcinogenesis. Cancer Prevention Research. 2(4). 330–337. 30 indexed citations
17.
Shaw, Alice T., Beow Y. Yeap, Mari Mino–Kenudson, et al.. (2009). Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK. Journal of Clinical Oncology. 27(26). 4247–4253. 1463 indexed citations breakdown →
18.
McDermott, Ultan, A. John Iafrate, Shyamala Maheswaran, et al.. (2009). Ligand-Dependent Platelet-Derived Growth Factor Receptor (PDGFR)-α Activation Sensitizes Rare Lung Cancer and Sarcoma Cells to PDGFR Kinase Inhibitors. Cancer Research. 69(9). 3937–3946. 83 indexed citations
19.
Montagut, Clara, Sreenath V. Sharma, Toshi Shioda, et al.. (2008). Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma. Cancer Research. 68(12). 4853–4861. 405 indexed citations
20.
McDermott, Ultan, A. John Iafrate, Nathanael S. Gray, et al.. (2008). Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors. Cancer Research. 68(9). 3389–3395. 312 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cyril H. Benes Breakdown of academic impact, for papers by Simon Forbes Breakdown of academic impact, for papers by Sarat Chandarlapaty Breakdown of academic impact, for papers by Aik Choon Tan Breakdown of academic impact, for papers by Mathew J. Garnett Breakdown of academic impact, for papers by Michael A. Davies Breakdown of academic impact, for papers by Barry S. Taylor Breakdown of academic impact, for papers by Jeffrey R. Infante Breakdown of academic impact, for papers by Jeff Settleman Breakdown of academic impact, for papers by Brian Schwartz
Rankless by CCL
2026